Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 01, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
Received FDA approval for CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the first and only FDA-approved treatment for depressive episodes associated with...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
February 22, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 07, 2022 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Prices Public Offering of Common Stock
January 04, 2022 22:05 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
January 03, 2022 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
December 20, 2021 06:47 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
December 06, 2021 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...